Skip to Content

Join the 'Breast Cancer, Metastatic' group to help and get support from people like you.

Breast Cancer, Metastatic News

Related terms: Metastatic Breast Cancer

Has Your Doc Been Touched by Breast Cancer? It Could Influence Care

Posted 7 days ago by Drugs.com

MONDAY, Dec. 11, 2017 – Having a personal connection to breast cancer seems to make doctors more likely to recommend routine breast cancer screenings, a new study finds. A survey of 848 doctors across the United States found they were more likely to recommend routine mammograms for younger and older women if the doctor knew someone who'd had advanced breast cancer and had not undergone breast cancer screening. The person might have been a patient, family member or friend of the doctor. The recommendation for screening was given despite the existence of conflicting guidelines on routine screening for those age groups, the researchers said. The American Cancer Society recommends personalized decisions for women aged 40 to 44, annual screening for women starting at age 45 and biennial screening (every other year) for women 55 and older. The U.S. Preventive Services Task Force recommends ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer, Prevention, Breast Cancer - Palliative, Diagnosis and Investigation

New Breast Cancer Drug Ribociclib (Kisqali) May Benefit Younger Women, Too

Posted 12 days ago by Drugs.com

WEDNESDAY, Dec. 6, 2017 – Adding a new drug to standard treatment can slow the progression of advanced breast cancer in younger women, a new clinical trial has found. The drug, called ribociclib (Kisqali), was approved by the U.S. Food and Drug Administration in March for the treatment of postmenopausal women with advanced breast cancer. Now, experts say, the drug is just as effective for premenopausal women. In the trial, the treatment typically doubled the time a woman remained free of cancer progression – from roughly one year to two years. That benefit is "strikingly similar" to what's been seen in postmenopausal women, said Dr. Neil Iyengar, who specializes in treating breast cancer at Memorial Sloan Kettering Cancer Center in New York City. Breast cancer occurs most often in older women, and tumors that develop before menopause tend to be more aggressive, explained Iyengar. ... Read more

Related support groups: Breast Cancer, Tamoxifen, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Tamoxifen Hexal, Nolvadex, Kisqali, Nolvadex D, Tamofen, Tamosin, Emblon, Ribociclib, Letrozole/ribociclib, Soltamox, Tamone, Tamoxen, Genox

Risk of Breast Cancer's Return Can Linger for Decades

Posted 8 Nov 2017 by Drugs.com

WEDNESDAY, Nov. 8, 2017 – Women treated for early stage breast cancer still face a substantial risk of recurrence up to 20 years later, a large, new study shows. Cancer experts say the findings should help inform women's treatment decisions. Specifically, the researchers followed women with estrogen-receptor-positive breast cancer, which means the hormone helps fuel the cancer's growth. Standard treatment includes hormonal therapy – with drugs that block estrogen's effects – to help prevent a return of the cancer. All of the women in the study, nearly 63,000, were scheduled to receive the typical five years of hormonal therapy. Researchers found that while the women remained cancer-free for those five years, the risk for recurrence over the next 15 years was still significant. It was greatest for women whose initial cancer had spread to multiple lymph nodes near the breast by the ... Read more

Related support groups: Cancer, Breast Cancer, Tamoxifen, Arimidex, Breast Cancer, Metastatic, Anastrozole, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer, Tamoxifen Hexal, Nolvadex, Soltamox, Tamone, Tamoxen, Genox, Nolvadex D, Tamofen, Tamosin, Emblon

Why Many Breast Cancer Patients Short-Circuit Their Treatment

Posted 7 Nov 2017 by Drugs.com

MONDAY, Nov. 6, 2017 – Many breast cancer patients skip recommended treatment after surgery because they lack faith in the health care system, a new study indicates. A patient survey found those who reported a general distrust of medical institutions and insurers were more likely to forgo follow-up breast cancer treatment, such as chemotherapy, hormone therapy or radiation. Trust or distrust of their own doctors did not emerge as a factor. "If we want more women with breast cancer to complete their treatment, we'll need to deal with their beliefs about the health care system – and I do think we can modify those beliefs," said study lead author Lorraine Dean. She's an assistant professor of epidemiology at Johns Hopkins University. Dean's team surveyed more than 2,700 patients in Florida and Pennsylvania after breast cancer surgery. More than 30 percent disregarded their doctor's ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Joan Lunden's Breast Cancer Journey: 'You Feel So Vulnerable'

Posted 26 Oct 2017 by Drugs.com

THURSDAY, Oct. 26, 2017 – Joan Lunden – co-host of "Good Morning America" for nearly two decades and a long-time health advocate – is now also a breast cancer survivor. By sharing her experience, Lunden hopes she can help other women facing a frightening cancer diagnosis. "It's so shocking when you hear you have cancer, and you feel so vulnerable," said Lunden, 67. Lunden never missed an annual mammogram to check for breast cancer. But each year, she said the process was "nerve-racking" because she has dense breast tissue that can make it difficult to distinguish healthy breast tissue from tumor tissue. Many women with dense breast tissue, particularly those with risk factors for breast cancer such as a family history, are advised to get additional testing – an MRI or sometimes an ultrasound. When Lunden went in for an ultrasound, she received shocking news. "I had an aggressive, ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Diagnosis and Investigation, Body Imaging

Breast Cancer More Lethal for Blacks Than Whites

Posted 16 Oct 2017 by Drugs.com

MONDAY, Oct. 16, 2017 – Differences in insurance are a major reason why black women are more likely to die of breast cancer than white women in the United States, a new study contends. "We found that differences in insurance explained one-third of the total excess risk of death in non-elderly black women compared to white women diagnosed with early stage breast cancer, while differences in tumor characteristics explained approximately one-fifth of the excess risk," lead study author Ahmedin Jemal, of the American Cancer Society (ACS), and colleagues wrote. In 2014, breast cancer death rates were 41 percent higher among black women than among white women in the United States, the researchers said. To learn more about this disparity, the investigators looked at information on more than 550,000 non-elderly women with early stage breast cancer. Black women were more likely to be uninsured ... Read more

Related support groups: Depo-Provera, Provera, Breast Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Breast Cancer, Metastatic, Anastrozole, Zoladex, Letrozole, Evista, Megace, Megestrol, Aromasin, Breast Cancer - Adjuvant, Casodex, Exemestane

More Women Choose Breast Reconstruction After Mastectomy

Posted 13 Oct 2017 by Drugs.com

FRIDAY, Oct. 13, 2017 – Over five years, the proportion of U.S. breast cancer patients opting for breast reconstruction after mastectomy grew by about two-thirds, a new government report shows. An analysis of patient data shows breast reconstruction followed 40 percent of breast-removal surgeries in 2014 – up from less than one-quarter in 2009, according to the U.S. Agency for Healthcare Research and Quality (AHRQ). Among age groups, women aged 65 and older accounted for the largest increase in breast reconstructive surgery – 140 percent. "This type of information is essential for policymakers and health systems seeking to keep pace with important trends in clinical care," Gopal Khanna, agency director, said in an AHRQ news release. The overall increase during the study period was 65 percent, researchers said. While reconstruction procedures increased in all insurance groups, the ... Read more

Related support groups: Surgery, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative

Breast Cancer Screenings Still Best for Early Detection

Posted 12 Oct 2017 by Drugs.com

THURSDAY, Oct. 12, 2017 – Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says. "Breast cancer can be treated more successfully if detected in its early phases, while it is small and has not yet spread," said Dr. Kathryn Evers, director of mammography at Fox Chase Cancer Center in Philadelphia. "With today's state-of-the-art treatment options and less extensive surgery, patients are experiencing better outcomes." Older age is a leading risk factor for breast cancer. Most women are diagnosed after the age of 50. Having certain mutations in the BRCA1 and BRCA2 genes also predispose women to the disease. And there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake ... Read more

Related support groups: Cancer, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer, Prevention, Breast Cancer - Palliative

Hormone Therapy May Be OK for Women With Migraines

Posted 11 Oct 2017 by Drugs.com

WEDNESDAY, Oct. 11, 2017 – Women who suffer from migraines may be able to safely use hormone therapy to treat menopause symptoms, a new study suggests. The study of 85,000 U.S. women found no evidence that hormone therapy carried a particular risk of heart attack or stroke among those with a history of migraine headaches. That possibility has been a concern, mainly based on studies of younger women with migraines. Those studies linked hormonal birth control pills to a small risk of stroke, particularly among women whose migraines feature "aura" symptoms – most often, visual disturbances such as seeing zigzag lines or bright flashes. Less has been known about any risks of hormone replacement therapy, said Dr. Jelena Pavlovic, the lead researcher on the new study. "It appears safe for women with migraines to use hormone therapy, in terms of their cardiovascular risk," said Pavlovic, an ... Read more

Related support groups: Plan B, Migraine, Depo-Provera, Mirena, Nexplanon, NuvaRing, Provera, Sprintec, Implanon, Ortho Tri-Cyclen, Microgestin Fe 1/20, Hot Flashes, Tri-Sprintec, Yasmin, Plan B One-Step, Loestrin 24 Fe, Ischemic Stroke, Ortho Evra, Breast Cancer, TriNessa

Double Mastectomy Increases Time Spent Off Work

Posted 9 Oct 2017 by Drugs.com

MONDAY, Oct. 9, 2017 – Working women who choose an aggressive treatment for breast cancer are likely to miss a significant amount of time before returning to the job. That's the conclusion of a study that focused on approximately 1,000 women in Georgia and Los Angeles who had to decide between various options for dealing with their cancer diagnosis. More than 60 percent of the women, aged 20 to 79, chose a lumpectomy, a relatively less aggressive intervention. One-third chose chemotherapy, while 16 percent had one breast removed (a unilateral mastectomy), the study authors said. Another 23 percent had both breasts removed (a bilateral mastectomy), which is considered the most aggressive option. Nearly 85 percent of the women had been working full-time prior to their diagnosis. Those who chose a bilateral mastectomy with breast reconstruction were eight times more likely to miss over a ... Read more

Related support groups: Surgery, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative

FDA Approves Verzenio (abemaciclib) for Certain Advanced or Metastatic Breast Cancers

Posted 1 Oct 2017 by Drugs.com

September 28, 2017 – The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Verzenio is approved to be given in combination with an endocrine therapy, called fulvestrant, after the cancer had grown on endocrine therapy. It is also approved to be given on its own, if patients were previously treated with endocrine therapy and chemotherapy after the cancer had spread (metastasized). "Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Verzenio, Abemaciclib

Verzenio Approved for Advanced Breast Cancer

Posted 29 Sep 2017 by Drugs.com

FRIDAY, Sept. 29, 2017 – Verzenio (abemaciclib) has been approved by the U.S. Food and Drug Administration to treat women with certain advanced forms of breast cancer, the most common cancer in the United States. More than 250,000 women are projected to be diagnosed with breast cancer this year, and more than 40,000 will die of the disease, the U.S. National Cancer Institute estimates. Verzenio is designed to block substances called cyclin-dependent kinases that are thought to spur the growth of cancer cells. The drug is approved for hormone receptor-positive and HER2-negative forms of advanced or spreading breast cancer that have been treated with a therapy that changes a person's hormones (endocrine therapy). "Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike [similar drugs], it can be given as a ... Read more

Related support groups: Breast Cancer, Breast Cancer, Metastatic, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Mastectomy Study Confirms 'Jolie Effect'

Posted 25 Sep 2017 by Drugs.com

MONDAY, Sept. 25, 2017 – Actress Angelina Jolie's decision to undergo breast removal to reduce her risk of breast cancer has led other women to do so, a new study shows. The findings show that celebrities can influence the health care decisions of the general public, said study author Art Sedrakyan, a professor at Weill Cornell Medicine in New York City. In early 2013, Jolie announced her decision to have the preventive surgery to have both breasts removed due to her elevated genetic risk for breast cancer. Researchers sought to determine the impact of that news by analyzing 2004-2014 data on risk-reducing mastectomy in New York State and New South Wales in Australia. In New York, they found the number of women undergoing the procedure nearly doubled – rising from 3.3 bimonthly cases per 1 million 20 months before Jolie's announcement to 6.3 cases per 1 million 20 months after her ... Read more

Related support groups: Surgery, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Osteolytic Bone Metastases of Breast Cancer

Breast Cancer Radiation 'Less Scary' Than Thought

Posted 25 Sep 2017 by Drugs.com

MONDAY, Sept. 25, 2017 – Radiation therapy for breast cancer is actually "less scary" than anticipated, nine out of 10 patients say after treatment. A survey of 300-plus breast cancer patients also found that more than 80 percent said the side effects of radiation were better than expected. "The word radiation itself sounds frightening and is associated with many negative news stories," said lead researcher Dr. Narek Shaverdian, of the University of California, Los Angeles (UCLA). But over the last 20 years, significant advances have been made, said Shaverdian, chief resident in radiation oncology at UCLA's David Geffen School of Medicine. "These changes allow us to spare critical organs, create an individual radiation plan for each patient, and also deliver radiation in more convenient schedules," he explained. Shaverdian and his team surveyed patients who had received radiation while ... Read more

Related support groups: Surgery, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Nausea/Vomiting - Radiation Induced, Osteolytic Bone Metastases of Breast Cancer, History - Radiation Therapy

Surgeons Play Big Role in Women's Choices for Breast Cancer Care

Posted 13 Sep 2017 by Drugs.com

WEDNESDAY, Sept. 13, 2017 – A breast cancer patient's choice of surgeon can have a major effect on her treatment, according to a new study. That's because surgeons have a strong influence on whether early stage cancer patients have both breasts removed even when cancer is found in only one breast – a procedure called contralateral prophylactic mastectomy (CPM). Researchers surveyed more than 3,300 women with early stage breast cancer and 349 surgeons who treated them. About 16 percent of the patients had both breasts removed. Only 4 percent of those whose surgeons heavily favored breast-saving surgery and were most reluctant to remove both breasts had the procedure. That compared to 34 percent of patients whose surgeons were most willing to do the surgery, the study found. "That difference is huge. Even for a procedure that is very patient-driven, we see that surgeons account for a ... Read more

Related support groups: Surgery, Breast Cancer, Breast Cancer, Metastatic, Breast Cancer - Adjuvant, Breast Cancer, Prevention, Breast Cancer - Palliative, Surgical Prophylaxis

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer

Related Drug Support Groups

tamoxifen, Arimidex, Femara, anastrozole, letrozole, Xeloda, Herceptin, Taxol, Taxotere, view more... Ibrance, Faslodex, capecitabine, paclitaxel, gemcitabine, Gemzar, eribulin, Kadcyla, Abraxane, Perjeta, Tykerb, Fareston, bevacizumab, fulvestrant, docetaxel, Tamoxifen Hexal, Kisqali, lapatinib, Nolvadex, pertuzumab, trastuzumab, Ixempra, ribociclib, paclitaxel protein-bound, Docefrez, Halaven, toremifene, Tamosin, Genox, Tamoxen, palbociclib, Nolvadex D, Tamofen, Emblon, Tamone, Soltamox, ixabepilone, ado-trastuzumab emtansine, Onxol, Ogivri